← Back to Search

Genetic Screening for Cancer

N/A

Waitlist Available

Led By Kenneth Offit, MD

Research Sponsored by Memorial Sloan Kettering Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients with a histologic diagnosis of cancer of the colon, breast, bladder, kidney, testicles, lungs, prostate, head and neck, or lymphoid organs, who have donated a diagnostic blood sample as either an inpatient or outpatient at MSKCC.

All patients who have two or more histologic diagnoses of the same primary tumor type involving the above sites.

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 20 years

Awards & highlights

Study Summary

This trial is looking at whether there is any link between cancer and genes. It is designed to help create ideas for future research.

Who is the study for?

This trial is for Ashkenazi Jewish individuals with a confirmed cancer diagnosis, including kidney, breast, colon, prostate, lung, ovarian, bladder cancers or lymphoid malignancies. Eligible participants must have donated a blood sample at MSKCC and can have multiple diagnoses of the same cancer type.Check my eligibility

What is being tested?

The study is exploring if there's a link between inherited genetic variations (germline polymorphisms) and various cancers using PCR/PCR/LDR strategy to analyze DNA. It aims to generate hypotheses for future research rather than test a treatment.See study design

What are the potential side effects?

Since this trial involves genetic testing without direct medical interventions like drugs or surgery, it does not typically present side effects in the traditional sense as seen with medication or surgical procedures.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have cancer in one of the specified organs and have given a blood sample at MSKCC.

Select...

I have had the same type of cancer diagnosed in two or more separate instances.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 20 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~20 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 20 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

To collect anonymized germline DNA from patients with breast, bladder, kidney, lung, colon, testicular, prostate, lymphoid, ovarian or head and neck cancers, as well as patients with multiple primary cancers, from select New York City ethnic groups.

Secondary outcome measures

To analyze DNA samples from matched non-cancer individuals of the same ethnic groups available as part of the AMDeC-sponsored New York Cancer Study.

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: 1Active Control1 Intervention

All incident second primary cancers of colon, breast, bladder, kidney, prostate, ovarian cancer lung cancer and lymphoid cancer diagnosed between 1999 and present will be included in the secondary design to compare second primary cancer "cases" and first primary "controls".

Group II: 2Placebo Group1 Intervention

Controls will be volunteer blood donors from the New York Blood Center as well as normal volunteers from other AMDeC sites.

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor

1,933 Previous Clinical Trials

564,539 Total Patients Enrolled

202 Trials studying Breast Cancer

60,056 Patients Enrolled for Breast Cancer

Weill Medical College of Cornell UniversityOTHER

1,054 Previous Clinical Trials

1,295,447 Total Patients Enrolled

29 Trials studying Breast Cancer

6,135 Patients Enrolled for Breast Cancer

Columbia UniversityOTHER

1,431 Previous Clinical Trials

2,439,750 Total Patients Enrolled

27 Trials studying Breast Cancer

2,418 Patients Enrolled for Breast Cancer

Media Library

1 Clinical Trial Eligibility Overview. Trial Name: NCT00579514 — N/A

Breast Cancer Research Study Groups: 2, 1

Breast Cancer Clinical Trial 2023: 1 Highlights & Side Effects. Trial Name: NCT00579514 — N/A

1 2023 Treatment Timeline for Medical Study. Trial Name: NCT00579514 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many subjects are being monitored in this research endeavor?

"Affirmative. Clinicaltrials.gov has data that substantiates this research effort is recruiting participants at present. It was first advertised on March 1, 2000 and its information most recently updated April 1st 2022; 35000 individuals are sought across a single clinical centre."

Answered by AI

Is there currently an opportunity for patient participation in this clinical trial?

"Indeed, clinicaltrials.gov confirms that this investigation is actively looking for participants. It was introduced on March 1st 2000 and updated most recently in April 2022; it seeks to enroll 35000 subjects from a single location."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients

2000. "Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00579514.

All > Lung Cancer Philadelphia > Kidney Cancer